Business
LEO Pharma Announces NICE Recommendation of Reimbursement in England and Wales
BALLERUP, Denmark, November 05, 2025--LEO Pharma announces NICE recommendation of reimbursement in England and Wales
About this update from Nice Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":366,"url":"https://media.zenfs.com/en/business-wire.com/0579f4efd8aaa7b5293783d845385b39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lqb90JqtDAHR8jbcUXz_2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTczMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0579f4efd8aaa7b5293783d845385b39","width":480,"height":366}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The National Institute for Health and Care Excellence (NICE) has recommended the first-and-only topical treatment for adults in the United Kingdom specifically approved for moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1","length":284,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Technology Appraisal Guidance (TAG) means NHS organisations in England and Wales must now make Anzupgo® ▼(delgocitinib) cream available for healthcare professionals to prescribe.","length":182,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"CHE affects around 4.4 million2,3 adults in the UK, with 70% of those with severe forms reporting problems performing everyday activities4, and 58% saying it interferes with their ability to work5.","length":197,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":663,"olType":false},{"type":"text","content":"BALLERUP, Denmark, November 05, 2025--(BUSINESS WIRE)--GLOBAL RELEASE - NOT INTENDED FOR UK MEDIA","length":97,"tagName":"p"},{"type":"text","content":"LEO Pharma, a global leader in medical dermatology, today announced that the National Institute for Health and Care Excellence (NICE) has issued Technology Appraisal Guidance (TAG) recommending the reimbursement of Anzupgo® ▼(delgocitinib) cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.1 Anzupgo® ▼ is now the first approved topical pan-Janus kinase (JAK) inhibitor treatment for this indication in England and Wales.1","length":530,"tagName":"p"},{"type":"text","content":"CHE is a fluctuating inflammatory skin disease, characterised by persistent itch, pain, redness and irritation on the hands and wrists.6 ...